Eribulin approval in advanced liposarcoma – successful drug or a weaker methodology?
Saved in:
| Main Authors: | Sameer Rastogi, Vineet Gupta |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=1;spage=2;epage=3;aulast=Rastogi |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01) -
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
by: Jonathan Noujaim, et al.
Published: (2016-01-01) -
Eribulin in Metastatic Breast Cancer: Actual Clinical Practice
by: A. V. Sultanbaev, et al.
Published: (2023-04-01) -
Weaker beta desynchronization indicates impaired emotion recognition in schizophrenia
by: Gábor Csukly, et al.
Published: (2025-03-01) -
Weaker Association Between Financial Security and Health in the Global South
by: Shervin Assari
Published: (2025-07-01)